Aurinia Pharmaceuticals, Inc. (AUPH)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Aurinia Pharmaceuticals, Inc. (AUPH)
Company Performance

Current Price

as of Oct 16, 2024

$7.18

P/E Ratio

N/A

Market Cap

$1.03B

Description

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Metrics

Overview

  • HQEdmonton, AB
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerAUPH
  • Price$7.18-0.28%

Trading Information

  • Market Cap$1.03B
  • Float89.99%
  • Average Daily Volume (1m)926,080
  • Average Daily Volume (3m)1,322,971
  • EPS-$0.35

Company

  • Revenue$207.11M
  • Rev Growth (1yr)37.83%
  • Net Income$0.72M
  • Gross Margin84.42%
  • EBITDA Margin7.19%
  • EBITDA$4.11M
  • EV$578.38M
  • EV/Revenue2.79
  • P/EN/A
  • P/S5.00
  • P/B2.82
Documents
SEC Filings
8-K (2024-09-12)
8-K (2024-08-01)
8-K (2024-06-14)
8-K (2024-05-02)
8-K (2024-02-29)
8-K (2024-02-15)
8-K (2024-01-05)
8-K (2023-11-02)
8-K (2023-09-21)
8-K (2023-08-21)
8-K (2023-08-03)
8-K (2023-07-03)
8-K (2023-05-17)
8-K (2023-05-04)
8-K (2023-04-05)
8-K (2023-03-13)
8-K (2023-02-28)
8-K (2023-01-27)
8-K (2023-01-09)
8-K (2023-01-03)
10-Q (2024-08-01)
10-Q (2024-05-02)
10-Q (2023-11-02)
10-Q (2023-08-03)
10-Q (2023-05-04)
10-K (2024-02-15)
10-K (2023-02-28)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Aurinia Pharmaceuticals Q3 ($ 7.72, +0.59) (2023-11-02T16:09:07Z)
Otsuka Holdings submits new drug application in Japan for Voclosporin in the treatment of patients with Lupus Nephritis (¥5412.0000, 0) (2023-11-10T06:22:39Z)
Aurinia presents data from AURORA program underscoring value of LUPKYNISⓇ (voclosporin) for patients with Lupus Nephritis at ACR 2023 ($8.42, +0.13) (2023-11-07T15:32:37Z)
Aurinia Pharmaceuticals trading higher ($9.90, +0.66) (2023-11-21T16:04:23Z)
Aurinia Pharmaceuticals reports Q3 EPS ($0.09) vs FactSet ($0.17) [7 est, ($0.19)-(0.13)] ($7.13, 0.00) (2023-11-02T10:13:47Z)
Aurinia Pharmaceuticals reports on multiple presentations at ASN 2023 ($7.88, 0.00) (2023-11-02T22:06:31Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-02)
Earnings Report (2023-08-03)
Factset
Factset Business Description